- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03224949
Comparison of ALD, NASH, and Healthy Control Patients
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Annette Bellar, MSLA
- Phone Number: 216-636-5247
- Email: bellara@ccf.org
Study Contact Backup
- Name: Revathi Penumatsa, MD
- Phone Number: 216 445-0688
- Email: penumar@ccf.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic Foundation
-
Contact:
- Megan Villareal, BS
- Phone Number: 216-636-5247
- Email: villarm@ccf.org
-
Contact:
- Annette Bellar, BS
- Phone Number: 216-636-5247
- Email: bellara@ccf.org
-
Principal Investigator:
- Srinivasan Dasarathy, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Alcoholic Steatosis Patients
Inclusion
- Fat accumulation (Steatosis) without signs of fibrosis/ inflammation in patients with alcohol abuse (alcohol intake >60 g/day in men and >40 g/day in women)
- Abnormal liver serum tests indicative of liver disease (elevated AST>ALT, y-glutamyl transpeptidase and bilirubin) .
Alcoholic Hepatitis with Mild Fibrosis
Inclusion
- Steatosis plus hepatocellular damage (presence of Mallory bodies and hepatocellular ballooning)
- Polymorphonuclear infiltrate
- Fibrosis stage 1-2
Alcoholic Hepatitis with Advanced Fibrosis
Inclusion
- Steatosis plus hepatocellular damage (presence of Mallory bodies and hepatocellular ballooning)
- Polymorphonuclear infiltrate
- Fibrosis stage 3-4.
Alcoholic Cirrhosis
Inclusion
- Fibrosis stage 4
- Presence of complications of cirrhosis such as esophageal varices with our without a previous episode of bleeding, splenomegaly, ascites, hepatic corroborate the diagnosis of cirrhosis.
Alcoholic Cirrhosis with HCC
Inclusion
-Diagnostic criteria of cirrhosis and established HCC. The diagnosis of HCC will be established based on histological confirmation or contrast-enhanced radiographic imaging according to the AASLD recommendations.
Exclusion
- BMI>35
- HBV
- Hemochromatosis
- Wilson's disease
- Autoimmune hepatitis
- Drug-inducted liver disease
- Hepatitis C
- Antitrypsin deficiency
- Patients who do not sign informed consent.
Non-alcoholic steatohepatitis
Inclusion -Biopsy proven NASH and chronic liver disease due to HCV patients.
Exclusion
- Cancer
- Diabetes
- Hypertension
- CAD or stroke
- Past history of liver disease
- Hepatitis C
- Antitrypsin deficiency
- Alcohol consumption of less than 7 drinks per week for women and less than 14 drinks per week for men
- BMI >35.
Healthy controls
Inclusion
-AUDIT-C score less than 4 in men and less than 3 in women.
Exclusion
- Cancer (except of non-melanoma skin cancer)
- Diabetes
- Hypertension
- Hypercholesterolemia
- Coronary artery disease or stroke
- History of current or past liver disease of any etiology
- BMI >27Kg/m2
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy controls
|
Patients will have a one time blood draw
|
Alcoholic hepatitis
|
Patients will have a one time blood draw
|
Alcoholic steatosis
|
Patients will have a one time blood draw
|
Alcoholic cirrhosis without HCC
|
Patients will have a one time blood draw
|
Nonalcoholic steatohepatitis (NASH)
|
Patients will have a one time blood draw
|
Alcoholic cirrhosis with HCC
|
Patients will have a one time blood draw
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biorepository
Time Frame: This is a 5 year study
|
The goal of this study is to create a biorepository of samples from patients with different types of liver disease compared to each other and healthy controls
|
This is a 5 year study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Srinivisan Dasarathy, MD, Staff
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-718
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ALD - Alcoholic Liver Disease
-
University Hospital, AngersRecruitingLiver Fibrosis | Non-alcoholic Fatty Liver Disease (NAFLD) | Alcoholic Liver Disease (ALD)France
-
Naga P. ChalasaniDSM Nutritional Products, Inc.CompletedNon-Alcoholic Fatty Liver Disease | Non-Alcoholic Steatohepatitis | Non-Alcoholic Fatty LiverUnited States
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Puerta de Hierro University HospitalHospital Universitario Marqués de ValdecillaNot yet recruitingNon-Alcoholic Fatty Liver Disease | Non Alcoholic SteatohepatitisSpain
-
Michael Ohliger, MD PhDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingNAFLD | Non-Alcoholic Fatty Liver Disease | NASH | Non Alcoholic Fatty Liver | Non Alcoholic SteatohepatitisUnited States
-
Better TherapeuticsArizona Liver HealthCompletedNon-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty LiverUnited States
-
National University Hospital, SingaporeWilmar InternationalEnrolling by invitationNAFLD | Non-Alcoholic Fatty Liver Disease | Non-Alcoholic SteatohepatitisSingapore
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
Nehal Abou SeadaCompletedNon-Alcoholic Fatty Liver Disease
-
National Taiwan University HospitalMinistry of Science and Technology, TaiwanRecruitingNon-Alcoholic Fatty Liver Disease | Non-Alcoholic Steatohepatitis | Bariatric SurgeryTaiwan
Clinical Trials on Blood draw
-
Abbott Point of CareNot yet recruitingPrecision of Potassium (K) Test in Capillary Whole Blood
-
University Hospital, Strasbourg, FranceNot yet recruitingKidney Transplantation | Humoral Rejection | Kidney Allograft Biopsy | Microvascular Inflammation
-
Vanderbilt-Ingram Cancer CenterWren Laboratories LLCCompletedMelanomaUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Turtle Health, Inc.Completed
-
National Heart Centre SingaporeDuke-NUS Graduate Medical SchoolRecruiting
-
Duke UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingHematologic MalignancyUnited States
-
University of BonnRecruitingSARS-CoV 2 | COVIDGermany
-
Joseph M. Still Research Foundation, Inc.RecruitingInflammatory Response | Deep Vein Thrombosis | Multi Organ Failure | Nosocomial InfectionUnited States